According to filings with the U.S. Securities and Exchange Commission, Inomagen Therapeutics is raising up to $6,626,079.00 in new funding. Sources indicate that as part of senior management President, Rishi Arora played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inomagen Therapeutics
Inomagen Therapeutics Is A Private, Preclinical-Stage Biotechnology Company Developing A Non-Viral Gene Therapy That Targets The Underlying Mechanisms Of Atrial Fibrillation. To Achieve Safe And Effective Gene Delivery, The Company Is Developing A Novel, Patented Transcatheter Gene Delivery System. Atrial fibrillation is the most common sustained heart rhythm disorder and a growing epidemic in an aging population.  Unfortunately, current therapies have proven ineffective for many patients as they do not address the underlying mechanisms of the disease. At Inomagen, we are exclusively focused on discovering and developing transformative gene therapies to markedly improve the treatment of atrial fibrillation.  Our scientific advancements have been the result of significant non-dilutive grant funding.  The company has an exclusive license agreement with Northwestern University for a robust IP estate and has assembled a highly experienced team to bring our therapies to market. Inomagen is located in Chicago’s Fulton Market as a portfolio member of Portal Innovations – a Biotech Incubator with an expansive space designed to provide best-in-class, fully equipped wet/dry lab and work space.

To learn more about Inomagen Therapeutics, visit http://inomagen.com/

Contact:
Rishi Arora, President
312-961-8166

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.